Shalin Shah is a distinguished leader in the field of metabolic health, specializing in testosterone replacement therapy. As the Chief Executive Officer of Marius Pharmaceuticals, he was instrumental in the development and FDA approval of KYZATREX® (testosterone undecanoate) CIII Capsules, an oral testosterone treatment for adult men with low or no testosterone levels due to certain medical conditions.
With a global investment background, Shalin transitioned into healthcare with a mission to revolutionize the industry through metabolic health. His leadership at Marius Pharmaceuticals is marked by innovative strategies that prioritize consumer access and education. Under his guidance, KYZATREX has been launched via consumer-focused channels that include preeminent national healthcare institutions, private-equity-backed medical practices, and national telemedicine platforms.
Shalin’s expertise extends beyond corporate leadership; he is an influential voice in longevity medicine and an advocate for reevaluating testosterone medication regulations. His efforts aim to reshape public perception and education on testosterone therapy and its significance for global health. He believes that oral testosterone replacement therapy has created a much-awaited paradigm shift, which is critical for addressing the worldwide men’s (and women’s) health crisis, marked by declining testosterone levels and lower life expectancies. His message is that testosterone replacement therapy is not just about adding years to life but also about adding life to years.